Revolutionazing the detection and prevention of cancer metastasis with the Internet of BioThings (www.selas-view.eu)
SELAS-VIEW aims to introduce a sound, credible, internationally competitive and innovative personalized and multifunctional and multifunctional (bioengineering + quantitative analytics + mobile Health) Platform for minimally-invasive, long-term, in vivo continuous monitoring of lung cancer (LC), the leading cause of cancer deaths. A pre-clinically validated platform for LC metastasis to the brain, the most intractable and economically unviable case, will serve as the project’s Minimally Viable Product. The platform will consist of: (i) a personalised, implantable biosensor to detect circulating biomarkers of metastasis and convert the detected molecules into an optical signal. The biosensor, based on patient cells, is grown for subcutaneous delivery in (ii) a “biosensor delivery capsule” comprised of biomaterial located inside a stainless steel syringe; (iii) a patient wrist-band monitor, a watch-like device to detect the light emitted and alert the patient; (iv) a customized mobile application to communicate with the monitor, process the detected emission, infer the presence of 
molecules released by metastatic cells and inform the patient and the physician. With further development and long-term exploitation this prototype has the great potential to be translated to an Internet of Things (IoT) Platform, offering a novel precision medicine solution. This Platform will be leading towards a global and sustainable transformation of the metastasis market, principally addressing the emerging Brain Metastasis niche market and ushering the partners to the burgeoning industries of live implantable biosensors and IoT, thus rapidly expanding markets, offering a vast commercial opportunity.
FUNDING:
The project SELAS-VIEW, ENTERPRISES/0223/Sub-Call1/0220 was funded by the Research and Innovation Foundation, under the «Research in Enterprises» Programme and through the Recovery and Resilience Facility of the NextGenerationEU instrument.